Financhill
Back

Nxera Pharma Quote, Financials, Valuation and Earnings

Nxera Pharma Price Quote

$6.16
+0.00 (+-8.74%)
(Updated: December 21, 2024 at 5:47 AM ET)

Nxera Pharma Key Stats

Sell
18
Nxera Pharma (SOLTF) is a Sell

Day range:
$6.16 - $6.16
52-week range:
$6.16 - $13.43
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
2.79
P/B ratio:
1.17%

Volume:
50
Avg. volume:
147
1-year change:
-37.3%
Market cap:
$553.6M
Revenue:
$91M
EPS:
$-0.27

How Much Does Nxera Pharma Make?

Data Unavailable

Is Nxera Pharma Growing As A Company?

Data Unavailable

Nxera Pharma Stock Price Performance

  • Did Nxera Pharma Stock Go Up Last Month?
    Nxera Pharma share price went down by -23.53% last month
  • Did SOLTF's Share Price Rise Over The Last Year?
    SOLTF share price fell by -37.3% over the past 1 year

What Is Nxera Pharma 52-Week High & Low?

Nxera Pharma Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Nxera Pharma?

Data Unavailable

Is Nxera Pharma Cash Flow Positive?

Data Unavailable

Nxera Pharma Return On Invested Capital

Data Unavailable

Nxera Pharma Earnings Date & Stock Price

  • What Is Nxera Pharma's Stock Price Today?
    A single share of SOLTF can be purchased today for 6.16
  • What Is Nxera Pharma’s Stock Symbol?
    Nxera Pharma trades on the otcm under the ticker symbol: SOLTF
  • When Is Nxera Pharma’s Next Earnings Date?
    The next quarterly earnings date for Nxera Pharma is scheduled on December 22, 2024
  • When Is SOLTF's next ex-dividend date?
    Nxera Pharma's next ex-dividend date is March 27, 2015
  • How To Buy Nxera Pharma Stock?
    You can buy Nxera Pharma shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

Nxera Pharma Competitors

  • Who Are Nxera Pharma's Competitors?
    Below is a list of companies who compete with Nxera Pharma or are related in some way:
    • AnGes Inc (AMGXF)
    • Healios KK (HLOSF)
    • PeptiDream Inc (PPTDF)
    • SanBio Co Ltd (SNBIF)
    • Takeda Pharmaceutical Co Ltd (TAK)

Nxera Pharma Dividend Yield

Data Unavailable

Nxera Pharma Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 0%
Revenue: 170.67% 0%

Analyst Recommendations

Buy Recommendations: 0
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 0.00
Downside from Last Price: -100%

Major Shareholders

Data Unavailable